Strengthening tuberculosis (TB) prevention, diagnosis, treatment, and surveillance in Asia
Closed Posted
- Opportunity number
- CDC-RFA-JG-26-0125
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Higher Education Inst. (Public)
- Public or Indian Housing Auth.
- Higher Education Inst. (Private)
- Independent School Districts
- State Governments
- Special District Governments
- 501(c)(3) Nonprofits
- Unrestricted
- For Profit Organizations
- City/Township Governments
- County Governments
- Tribal Governments (Federally Recognized)
- Tribal Organizations (Not Federally Recognized)
- Non-501(c)(3) Nonprofits
- Small Businesses
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention is soliciting cooperative agreement applications to strengthen tuberculosis prevention, diagnosis, treatment, and surveillance in India, the Philippines, and Vietnam, with applications due by 11:59 p.m. Eastern Time on June 22, 2026.
Eligibility is unrestricted; all organization types may apply, including state and local governments, nonprofits, institutions of higher education, for-profit entities, and foreign-based organizations. Applicants must conduct projects in one of the three target countries and provide country-specific documentation: India applicants must submit active Foreign Contribution Regulation Act (FCRA) registration; Vietnam applicants must provide a Registration Certificate for foreign applicants or Certificate of Establishment/Juridical Person Status for local recipients. Failure to provide required certifications renders applications non-responsive.
The CDC anticipates approximately $3,000,000 in Year 1 funding with 1–3 awards anticipated. Applicants are strongly encouraged to request an Average One Year Award Amount of $1,000,000 per country; applicants requesting more than $1,000,000 for Year 1 will be deemed non-responsive. Awards are structured as five-year cooperative agreements consisting of five 12-month budget periods. Indirect costs may be charged using an approved negotiated rate or the de minimis rate of 15% of modified total direct costs.
The NOFO emphasizes two primary strategies: enhancing early diagnosis and treatment of TB and drug-resistant/multidrug-resistant TB while maximizing linkages within the care cascade, and strengthening TB surveillance for data-driven decision-making. Applicants must implement activities addressing TB case finding, TB preventive treatment (TPT), treatment linkage, and surveillance system improvements. Merit review will score applications on Approach (40 points), Organizational Capacity (35 points), and Data, Monitoring, and Evaluation (25 points), for a total of 100 points. Recipients must dedicate approximately 5–10% of project funding to monitoring, reporting, and evaluation activities. The CDC expects substantial involvement, including assistance with key personnel and sub-recipient selection, technical support and capacity building, and oversight to ensure alignment with national TB program plans. The award number is CDC-RFA-JG-26-0125; assistance listing 93.494.
Synopsis
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $3,000,000 for Year 1, subject to the availability of funds.The purpose of this NOFO is to reduce TB-related morbidity and mortality in India, the Philippines, and Vietnam by strengthening:• TB case finding, including linked activities such as screening, testing, and diagnostic evaluation.• TB prevention, including TB preventive treatment (TPT).• TB treatment, including linkage and improved treatment regimens, as appropriate.• Surveillance, through adopting, evaluating, and expanding innovative approaches.Activities implemented will focus on:• Expanding and improving diagnosis of TB infection and TB disease, including early and asymptomatic TB as well as drug-resistant or multidrug-resistant TB. This will be done by using and evaluating innovative screening and diagnostic methods and scaling up evidence-based approaches. • Improving TPT outcomes for all individuals at high risk of developing TB disease and improving TB treatment outcomes of individuals with TB disease, including those with drug-resistant or multidrug-resistant TB. This will be done by using new, shorter, and better-tolerated treatment regimens.• Strengthening TB surveillance for data-driven decision making, program planning, and public health action.Asia carries the highest burden of TB and drug-resistant or multidrug-resistant TB globally. This NOFO will focus on activities in India, the Philippines, and Vietnam because they are three of the top four countries contributing to the TB burden in the U.S. This aligns with the America First Global Health Strategy.
Files
| File | Type | Posted |
|---|---|---|
| cdc-rfa-jg-26-0125_final.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity